• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

法尼醇X受体拮抗剂的研究进展

甘侠, 年四昀, 王国平

甘侠, 年四昀, 王国平. 法尼醇X受体拮抗剂的研究进展[J]. 中国药科大学学报, 2016, 47(5): 521-530. DOI: 10.11665/j.issn.1000-5048.20160503
引用本文: 甘侠, 年四昀, 王国平. 法尼醇X受体拮抗剂的研究进展[J]. 中国药科大学学报, 2016, 47(5): 521-530. DOI: 10.11665/j.issn.1000-5048.20160503
shu
GAN Xia, NIAN Siyun, WANG Guoping. Advances in the development of farnesoid X receptor antagonists[J]. Journal of China Pharmaceutical University, 2016, 47(5): 521-530. DOI: 10.11665/j.issn.1000-5048.20160503
Citation: GAN Xia, NIAN Siyun, WANG Guoping. Advances in the development of farnesoid X receptor antagonists[J]. Journal of China Pharmaceutical University, 2016, 47(5): 521-530. DOI: 10.11665/j.issn.1000-5048.20160503
shu

法尼醇X受体拮抗剂的研究进展

  • 1.

    中国医药工业研究总院 上海医药工业研究院

  • 2.

    扬州奥锐特药业有限公司

基金项目: 上海市科学技术委员会“创新行动计划”生物医药领域科技成果转化应用项目资助项目(No.16431903900)

Advances in the development of farnesoid X receptor antagonists

摘要

    摘要
  • 摘要: 法尼醇X受体(FXR)属于核受体超家族一员，在胆汁酸、三酰甘油、葡萄糖等的动态平衡中发挥重要作用。FXR拮抗剂可通过提高胆固醇7α-羟化酶(CYP7A1)的活性而促进总胆固醇向胆汁酸转化，同时调节相关靶基因降低三酰甘油、低密度脂蛋白以及升高高密度脂蛋白水平。因此，FXR拮抗剂有望成为治疗高脂血症的新型药物。近年来，FXR拮抗剂的研究取得了较大进展，已获得多种结构类型的FXR拮抗剂。本文就近年来报道的FXR拮抗剂进行综述。
    Abstract: Farnesoid X receptor(FXR), a member of the nuclear receptor superfamily, plays an important role on the regulating bile acid, lipid and glucose homeostasis. FXR antagonist can stimulate the conversion of total cholesterol into bile acid by improving the activity of CYP7A1. It can also reduce the content of triglyceride, low-density lipoprotein and increase that of high-density lipoprotein by regulating the relevant target genes. Considering the above facts, FXR antagonist is expected to become a potential drug to treat hyperlipidemia. In recent years, great progress has been made in the research on FXR antagonists with their various structural types having been obtained. This article introduces natural and synthetic FXR antagonists reported in recent years.
    • HTML全文
    • 参考文献(34)
  • [1] Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites[J].Cell,1995,81(5):687-693.
    [2] Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids[J].Science,1999,284(5418):1362-1365.
    [3] Mazuy C,Helleboid A,Staels B,et al.Nuclear bile acid signaling through the farnesoid X receptor[J].Cell Mol Life Sci,2015,72(9):1631-1650.
    [4] Fiorucci S,Rizzo G,Donini A,et al.Targeting farnesoid X receptor for liver and metabolic disorders[J].Trends Mol Med, 2007,13(7):298-309.
    [5] Amano Y, Shimada M, Miura S, et al. Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates[J].Eur J Pharmacol,2014,723:108-115.
    [6] Urizar NL,Liverman AB,Dodds DT,et al.A natural product that lowers cholesterol as an antagonist ligand for FXR[J].Science,2002,296(5573):1703-1706.
    [7] Cui J, Huang L, Zhao A, et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump[J].J Biol Chem,2003,278(12):10214-10220.
    [8] Burris TP,Montrose C,Houck KA,et al.The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand[J].Mol Pharmacol,2005,67(3):948-954.
    [9] Carter BA,Taylor OA,Prendergast DR,et al.Stigmasterol,a soy lipid-derived phytosterol,is an antagonist of the bile acid nuclear receptor FXR[J].Pediatr Res,2007,62(3):301-306.
    [10] De Marino S,Ummarino R,D′Auria MV,et al.Theonellasterols and conicasterols from Theonella swinhoei.Novel marine natural ligands for human nuclear receptors[J].J Med Chem,2011,54(8):3065-3075.
    [11] Sepe V,Bifulco G,Renga B,et al.Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor[J].J Med Chem, 2011,54(5):1314-1320.
    [12] Putra MY,Bavestrello G,Cerrano C,et al.Polyhydroxylated sterols from the Indonesian soft coral Sinularia sp.and their effect on farnesoid X-activated receptor[J].Steroids,2012,77(5):433-440.
    [13] Kumar D,Khanna AK,Pratap R,et al.Dose escalation pharmacokinetics and lipid lowering activity of a novel farnesoid X receptor modulator:16-dehydropregnenolone[J].Indian J Pharmacol,2012,44(1):57-62.
    [14] Nam SJ, Ko H, Shin M, et al. Farnesoid X-activated receptor antagonists from a marine sponge Spongia sp.[J].Bioorg Med Chem Lett,2006,16(20):5398-5402.
    [15] Nam SJ, Ko H, Ju MK, et al. Scalarane sesterterpenes from a marine sponge of the genus Spongia and their FXR antagonistic activity[J].J Nat Prod,2007,70(11):1691-1695.
    [16] Choi H,Hwang H,Chin J,et al.Tuberatolides,potent FXR antagonists from the Korean marine tunicate Botryllus tuberatus[J].J Nat Prod,2011,74(1):90-94.
    [17] Di Leva FS,Festa C,D′Amore C,et al.Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors.design,synthesis,and biological evaluation of novel ligands[J].J Med Chem,2013,56(11):4701-4717.
    [18] Dussault I,Beard R,Lin M,et al.Identification of gene-selective modulators of the bile acid receptor FXR[J].J Biol Chem,2003,278(9):7027-7033.
    [19] Kainuma M,Makishima M,Hashimoto Y,et al.Design,synthesis,and evaluation of non-steroidal farnesoid X receptor(FXR)antagonist[J].Bioorg Med Chem,2007,15(7):2587-2600.
    [20] Huang H,Yu Y,Gao Z,et al.Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel,potent,and nonsteroidal farnesoid X receptor(FXR)selective antagonists[J].J Med Chem,2012,55(16):7037-7053.
    [21] Ma RQ.The design,synthesis and biological evaluation of FXR antagnists and the research on microwave-assisted one-pot synthesis of 4-arylidene-pyrazolone derivatives( FXR拮抗剂的设计、合成与药理活性研究及4-芳亚甲基取代吡唑酮类衍生物的方法学研究)[D].Shanghai:East China University of Science and Technology,2011.
    [22] Yu DD,Lin W,Forman BM,et al.Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor[J].Bioorg Med Chem,2014,22(11):2919-2938.
    [23] Huang H,Si P,Wang L,et al.Design,synthesis,and biological evaluation of novel nonsteroidal farnesoid X Receptor(FXR)antagonists:molecular basis of FXR antagonism[J].Chem Med Chem,2015,10(7):1184-1199..
    [24] Amano Y,Ishikawa E,Shinozawa E,et al.Combinational effects of farnesoid X receptor antagonist and statin on plasma lipid levels and low-density lipoprotein clearance in guinea pigs[J].Life Sci,2014,108(1):7-12.
    [25] Liu P,Xu X,Chen L,et al.Discovery and SAR study of hydroxyacetophenone derivatives as potent,non-steroidal farnesoid X receptor(FXR)antagonists[J].Bioorg Med Chem Lett,2014,22(5):1596-1607.
    [26] Liu P.The design,synthesis and SAR studies of two types of FXR antagonists and the exploring of aryne in several reactions(两类FXR拮抗剂的设计、合成与构效关系研究及芳炔参与的反应研究)[D].Shanghai:East China University of Science and Technology,2014.
    [27] Xu X,Xu X,Liu P,et al.Structural basis for small molecule NDB(N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino)benzamide)as a selective antagonist of farnesoid X receptor α(FXRα)in stabilizing the homodimerization of the receptor[J].J Biol Chem,2015,290(32):19888-19899.
    [28] Merk D,Lamers C,Ahmad K,et al.Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators:development of a highly potent partial farnesoid X receptor agonist[J].J Med Chem,2014,57(19):8035-8055.
    [29] Fu J,Si P,Zheng M,et al.Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking[J].Bioorg Med Chem Lett,2012,22(22):6848-6853.
    [30] Wang L,Si P,Sheng Y,et al.Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening[J].Chem Biol Drug Des, 2015,85(4):481-487.
    [31] Liu Z, Law WK, Wang D, et al. Synthesis and discovery of andrographolide derivatives as non-steroidal farnesoid X receptor(FXR)antagonists[J].RSC Adv,2014,4(26):13533-13545.
    [32] Kaimal R,Song X,Yan B,et al.Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones[J].J Pharmacol Exp Ther,2009,330(1):125-134.
    [33] Lu W,Cheng F,Jiang J,et al.FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach[J].Sci Rep,2015,5:8114.
    [34] Schmidt J, Klingler FM, Proschak E, et al. NSAIDs Ibuprofen,indometacin,and diclofenac do not interact with farnesoid X receptor[J].Sci Rep,2015,5:14782.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1074
  • HTML全文浏览量:  1
  • PDF下载量:  3646
  • 被引次数: 0
出版历程
  • 刊出日期:  2016-10-24

目录

摘要
HTML全文
    参考文献(34)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：336236

    x 关闭 永久关闭